Previous close | 54.32 |
Open | 54.79 |
Bid | 54.21 x 100 |
Ask | 54.51 x 200 |
Day's range | 53.70 - 55.62 |
52-week range | 19.81 - 61.61 |
Volume | |
Avg. volume | 1,048,309 |
Market cap | 3.651B |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.73 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 87.42 |
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedbackUTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the
Key Insights Significantly high institutional ownership implies Merus' stock price is sensitive to their trading...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in second line (2L) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics